Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28771360 | 0.94 | PPARG (0.47) | PTGDR2PPARGALOX5PTGESFFAR1 | |
| SCHEMBL3216344 | 0.89 | PPARG (0.44) | PTGDR2PPARGALOX5PTGESPSEN1 | |
| SCHEMBL3218168 | 0.88 | PPARG (0.60) | PPARGFFAR1 | |
| SCHEMBL27716303 | 0.85 | PPARG (0.42) | PTGDR2PPARGALOX5PTGESPSEN1 | |
| SCHEMBL5111582 | 0.84 | PPARG (0.41) | PTGDR2PPARGALOX5PTGES | |
| SCHEMBL3194488 | 0.84 | PPARG (0.69) | PPARG | |
| SCHEMBL3215812 | 0.83 | PTGDR2 (0.48) | PTGDR2PPARGALOX5PTGES | |
| SCHEMBL5113068 | 0.82 | PPARG (0.39) | PTGDR2PPARGALOX5PTGES | |
| SCHEMBL27737185 | 0.82 | PPARG (0.58) | PPARGFFAR1 | |
| SCHEMBL3208104 | 0.80 | PPARG (0.46) | PTGDR2PPARGALOX5PTGESPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PTGDR2 1289/4885PPARG 31/4885ALOX5 583/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PTGDR2 1005/4885PPARG 30/4885ALOX5 757/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PTGDR2 1289/4885PPARG 31/4885ALOX5 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.